Lidocaine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lidocaine: From Local Anesthesia to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Lidocaine is a well-established Na⁺ channel blocker widely used as a local anesthetic and Class Ib antiarrhythmic agent. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, achieving a prediction score of 99.99%, however no clinical trials and no supporting publications have been identified for this specific indication — evidence is currently limited to model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Local anesthesia / cardiac arrhythmia (no India regulatory registration on file) |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in this Evidence Pack. Based on established pharmacology, Lidocaine is a Na⁺ channel blocker that inhibits neuronal membrane depolarization by blocking voltage-gated sodium channels, producing local anesthesia and — at systemic doses — antiarrhythmic effects (Class Ib). Its use as a topical ocular surface anesthetic is well-established in ophthalmic clinical practice worldwide.
In the context of punctate epithelial keratoconjunctivitis (PEK) — a condition characterized by scattered punctate epithelial defects across the corneal and conjunctival surface, often accompanied by ocular discomfort — Lidocaine’s analgesic mechanism could theoretically address acute pain arising from exposed corneal nerve endings. Sodium channel blockade may additionally confer mild anti-inflammatory properties by reducing neurogenic inflammation via suppression of neuropeptide release (e.g., Substance P), providing a biologically plausible, albeit indirect, connection to PEK symptom management.
However, this prediction carries a critical biological caveat. PEK arises from diverse etiologies including drug toxicity, post-infectious sequelae, and dry eye disease. Prolonged topical application of local anesthetics — including Lidocaine — is well-documented to inhibit corneal epithelial cell mitosis and delay wound healing, potentially worsening the very condition it might aim to treat. The high TxGNN score most likely reflects broad network-level similarity across ocular surface inflammation nodes in the knowledge graph rather than a direct, specific therapeutic mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials or publications directly support Lidocaine for punctate epithelial keratoconjunctivitis, and the well-documented corneal epitheliotoxicity associated with prolonged topical anesthetic use represents a mechanistic safety concern that must be addressed before this indication can advance.
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank to formally characterize anti-inflammatory potential
- India package insert retrieval and review for ophthalmic safety warnings and contraindications (currently blocking)
- Preclinical data distinguishing short-term analgesic benefit from long-term epithelial toxicity in PEK models
- Drug interaction (DDI) database query to be re-run after correcting the missing DDInter file path (
ddinter_code_A.csv) - Reassessment once India market status is clarified — Lidocaine formulations (gel, solution) may be available under different registration pathways not captured in the current data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.